Plozasiran prevents recurrent pancreatitis in most severe hypertriglyceridaemia

A post hoc analysis of data from the PALISADE trial has shown that plozasiran 25 or 50 mg s.c. quarterly for 12 months reduces recurrent pancreatitis in patients with familial chylomicronaemia syndrome (FCS) with a history of acute pancreatitis (AP) and extreme hypertriglyceridaemia.¹ This was accompanied by a reduction in need for AP-related hospitalisation.